Table 1 Patient characteristics (n = 7)
Patient | Age | Disease Stage | Number + Lymph Nodes | HER2 Status | Prior Treatment/s | Maintenance Hormones |
|---|---|---|---|---|---|---|
Vaccinations: immature DC (GM-CSF, IL-4) + HER2 ICD protein control DC loaded with KLH and tetanus toxoid | ||||||
#1 | 38 | T3pN3 – IIIC | > 10 | > 80% cells overexpress by IHC | AC-Taxol; trastuzumab | Raloxifene (ER/PR+) |
#2 | 56 | T1cpN2M1 – IV | 7 | 100% cells overexpress by IHC | Taxol; HDC + Auto PBSCT DC-CEA vaccine | Tamoxifen (ER/PR+) |
#3 | 57 | T3pN2 – IIIC | 7 | 3+ | doxorubicin HDC + Auto PBSCT | None (ER/PR-) |
Vaccinations: Mature DC (GM-CSF, IL-4, CD40-ligand, IFNγ) + HER2 ICD protein, E75 ECD peptide control DC loaded with KLH and CMV peptide | ||||||
#4 | 47 | T1pN2 – IIIA | 8 | 3+ | AC; Taxotere; Radiotherapy | None (ER/PR-) |
#5 | 58 | T2pN3 – IIIC | 11 | 2+ | FAC; Taxol; XRT | Tamoxifen (ER/PR+) |
#6 | 38 | IV (liver) | 0 | High | Taxotere; Trastuzumab (prior to enrollment and then continued on maintenance > 4 years); FAC; Navelbine; RFA of liver lesion | None (ER/PR-) |
Vaccinations: DC (FLT3-ligand) + GM-CSF + CD40-ligand + IFNγ+ HER2 ICD protein control DC loaded with KLH, tetanus toxoid and CMV peptide | ||||||
#7 | 45 | T4N1 vs N0M0 – IIIB | 0 @ surgery | 3+ in 100% cells by IHC | Neoadj AC; post-op Taxol; post-mastect RT | None (ER/PR-) |